Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Regulus Therapeutics (RGLS) Stock Price

Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.1449474259266 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently commented on RGLS. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective for the company. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Finally, Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $2.50.

Regulus Therapeutics (NASDAQ RGLS) opened at $1.20 on Friday. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $1.95. The company has a market cap of $124.75, a P/E ratio of -0.89 and a beta of 1.72.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Regulus Therapeutics (RGLS) Stock Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-regulus-therapeutics-rgls-stock-price.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply